Correction to Lancet Infect Dis 2025; published online Oct 10. https://doi.org/10.1016/S1473-3099(25)00482-7

No authors listed

Free article

Published Erratum

No authors listed. Lancet Infect Dis. 2026 Feb.

Free article

. 2026 Feb;26(2):e83.

doi: 10.1016/S1473-3099(25)00778-9. Epub 2025 Dec 17.

No abstract available

Erratum for

Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
Schilling WHK, Jittamala P, Wongnak P, Watson JA, Boyd S, Luvira V, Siripoon T, Ngamprasertchai T, Batty EM, Beer E, Singh S, Asawasriworanan T, Seers T, Phommasone K, Evans TJ, Kruabkontho V, Ngernseng T, Tubprasert J, Abdad MY, Madmanee W, Kouhathong J, Suwannasin K, Pagornrat W, Piteekan T, Hanboonkunupakarn B, Poovorawan K, Potaporn M, Srisubat A, Loharjun B, Chotivanich K, Imwong M, Pukrittayakamee S, Dondorp AM, Day NPJ, Piyaphanee W, Phumratanaprapin W, White NJ; PLATCOV Collaborative Group. Schilling WHK, et al. Lancet Infect Dis. 2026 Feb;26(2):139-147. doi: 10.1016/S1473-3099(25)00482-7. Epub 2025 Oct 11. Lancet Infect Dis. 2026. PMID: 41082886 Clinical Trial.